Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) is pleased to announce the proposal, "Development of applied technology for CRISPR/Cas9 genome editing using Bonac Nucleic Acid type sgRNA," has been selected as a grant project for the "Okinawa Prefecture Medical Industry Competitiveness Enhancement Project” for FY2015.

 

In this project, Bonac will develop an RNA-based system for efficient genome editing and gene expression induction by chemically synthesizing modifiable sgRNA using the "Bonac Nucleic Acid" technology. This project will enable the development of a new type of basic technology that has never been realized before, and we will promote research and development that will lead to the revitalization of medical-related industries.

 

Contact:

Corporate Affairs

press@bonac.co.jp